Wenzhou Kangning Hospital 2025 Annual Report: Key Highlights and Investor Insights

1. Solid Foundation and Shareholder Returns: Chairman’s Statement

Wenzhou Kangning Hospital Co., Ltd. continues to prioritize shareholder interests, implementing both profit distribution and a robust share repurchase plan throughout 2025. The company has rewarded shareholders by enhancing net assets and earnings per share through buybacks, clearly signaling management’s confidence in the Group’s future development and commitment to value creation.

• Share repurchase actions have further consolidated the company’s position in the capital markets.
• The company sees healthcare as a long-term value pursuit, focusing on steady, sustainable growth and leveraging opportunities within the sector.

2. Financial Performance and Dividend Announcements

Dividend Policy and 2025 Payouts

• The Proposed Final Dividend for 2025 is set at RMB3.2 per 10 shares (inclusive of tax), subject to shareholder approval at the AGM. The total cash dividend for the year (interim + final) will be RMB35.27 million, accounting for 64.8% of the net profit attributable to shareholders in the consolidated statements.
• Dividend payments: Domestic shareholders will be paid in RMB, and H share holders in HKD, based on the PBOC exchange rate before the AGM. The payment date is expected to be no later than July 8, 2026.
• Taxation: The company will withhold a 10%-20% tax on dividends distributed to non-resident enterprise and individual shareholders, depending on applicable tax treaties. Shareholders must liaise with their custodians if they seek preferential tax treatment.
• No shareholder has waived dividends as of December 31, 2025.

Key Financial Results

• Net profit attributable to shareholders: RMB54.4 million in 2025 (down from RMB65.6 million in 2024).
• Basic and diluted EPS: RMB0.76 (down from RMB0.88 in 2024).
• Distributable reserves: RMB364.2 million as of year-end.
• Total equity attributable to owners: RMB1.19 billion.

3. Share Repurchase and Equity Incentive Scheme

• The company repurchased 2,270,900 shares for a total consideration of HK\$24.52 million in 2025, with the aim of boosting EPS and NAV per share.
• No new securities or debentures were issued during the year.
• The Equity Incentive Scheme is ongoing, with 1,240,100 award shares granted (about 1.76% of total issued shares); 2,502,665 shares remain available for future grants. The scheme aims to better align management and employee interests with those of shareholders, strengthening long-term commitment and competitiveness.

4. Public Float Issues and Regulatory Developments

• Public float fell below the HKEX 25% threshold to 24.11%.
• To restore compliance, the company has applied for the conversion of 9,286,359 domestic shares into H shares, which upon completion will raise the public float to 37.3%.
• The CSRC’s increased workload has delayed this process; the company is actively engaging regulators and making monthly announcements to keep investors informed. No actions will be taken that further reduce the public float.
• This is a price-sensitive issue as continued non-compliance could affect trading liquidity or regulatory status.

5. Corporate Governance and Risk Management

• The company maintains robust risk management and internal control systems, reviewed annually by the Board and Audit Committee.
• No material weaknesses or breaches in financial, operational, or compliance controls were found in 2025.
• Remuneration: Senior management remuneration bands disclosed; the majority earn below RMB1.4 million.

6. Regulatory Compliance and Environmental Policies

• The Group operates in strict compliance with PRC national and local healthcare regulations, with no significant legal or regulatory breaches reported in 2025.
• The company maintains a strong focus on environmental responsibility, especially in medical waste management, utilizing qualified third parties and adhering to all laws and standards.

7. Other Material Matters

• Shareholder structure: Several institutional shareholders hold >5% each; Central Enterprises Rural Industry Investment Fund owns 10.32% of total capital.
• Employee and management incentives: The company continues to operate its Equity Incentive Scheme and H Share Award and Trust Scheme to attract and retain key personnel.
• Donations: Charitable contributions in 2025 totaled RMB3.1 million.
• No significant related party or connected transactions requiring special shareholder attention.
• No management contracts, new debentures, or equity-linked agreements entered in 2025.
• Important post-balance sheet event: The 2025 profit distribution plan (final dividend) is pending AGM approval, with a proposed payout of RMB22,527,712 before tax.

8. Amendments to Articles of Association

• The company’s Articles were amended in 2025 to align with the latest PRC company law and HKEX Listing Rules. The new Articles are effective from June 30, 2025.

Potential Price-Sensitive Issues for Shareholders

• Public float deficiency and pending regulatory approval for H share conversion. Any prolonged delay or regulatory non-compliance could affect share liquidity and value.
• Dividend payout ratio remains high at 64.8% of net profit, continuing to support shareholder returns.
• Ongoing share buybacks and incentive schemes could have a positive impact on EPS and share value.
• Stable financial performance but declining net profit and EPS compared to the prior year may be a concern for growth-oriented investors.

Disclaimer: This article is a summary and interpretation of Wenzhou Kangning Hospital’s 2025 Annual Report prepared for informational purposes only. It does not constitute investment advice. Actual investment decisions should be made based on your own due diligence and consultation with qualified professionals. The author is not responsible for actions taken based on this article.

View KN HOSPITAL Historical chart here